First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 6, 2006, Pages 953-956

  Schang, Luis M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antiviral drugs; Cellular protein kinases; Kaposi's sarcoma herpesvirus; Pharmacological inhibitors; Poxvirus; Viral pathogenesis; Viral replication

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; ANTIDIARRHEAL AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CANERTINIB; CELL PROTEIN; DAUNORUBICIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; PACLITAXEL; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; NEUTROPENIA; NONHUMAN; POXVIRUS INFECTION; VACCINIA VIRUS; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; HERPESVIRUS 8, HUMAN; HUMANS; MICE; PIPERAZINES; POXVIRIDAE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; VIRUS REPLICATION;

EID: 33846021965     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.6.953     Document Type: Article

References (12)

1. Yang H, Kim SIC, Kim M et at Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 115, 379-387 (2005).
2. Reeves PM, Bommarius B, Lebeis S et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med. 11, 731-739 (2005).
3. Koon HB, Bubley GJ, Pantanowitz L et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 23, 982-989 (2005).
4. Kim M, Yang H, Kim SK et al. Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. J. Biol. Chem. 279, 25838-25848 (2004).
5. Baselga J: Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J. Clin. Oncol. 20, 2217-2219 (2002).
6. Schang LM: Cyclin-dependent kinases as cellular targets for antiviral drugs. J. Antimicrob. Chemother. 50, 779-792 (2002).
7. Schang LM: Herpes simplex viruses in antiviral drug discovery. Curr. Pharm. Des. 12, 12, 1357-1370 (2006).
8. Moses AV, Jarvis MA, Raggo C. et al. Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J. Virol. 76, 8383-8399 (2002).
9. Sturzl M, Roth WK, Brockmeyer NH, Zietz C, Speiser B, Hofschneider PH: Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc. Natl. Acad. Sci. USA 89, 7046-7050 (1992).
10. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002).
11. Rubin BP, Schuetze SM, Eary JF et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 20, 3586-3591 (2002).
12. Cools J, DeAngelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201-1214 (2003).